/stocks — the workspaceLOADING
All ODTX SEC filings, by type → · Earnings date & implied move · Search inside filings
ODTX is not among the 142 companies we ingest every day, so it is not in the fundamentals screener or the size and group lists built from it. This page reads its SEC filings when the page is built. Ask us to add it: we keep a count per ticker and nothing about you.
Latest report (10-Q, filed 2026-08-06). Three months to 2026-06-30 against 2025-06-30: Revenue $0, down 100.0% from $959,000; Net loss $52.8M, 28.0% larger than $41.2M. Six months to 2026-06-30 against 2025-06-30: Operating cash used $75.5M, 3.7% larger than $72.9M. Read it line by line, each linked to its source → · Every report →
Odyssey Therapeutics, Inc. (ODTX) is a biological products, (no diagnostic substances) company. Fundamentals from SEC filings; prices are end-of-day.
Every filed figure on this page is free to read, dated and sourced; no column is held back for a paid plan. Each section with figures says what date they are true as of and where they come from.
What’s behind ODTX’s latest move — the size, how unusual the volume is, and the catalyst on the tape, explained and cited to the source.
End-of-day bars · delayed, not real-time · data: Databento · studies computed in your browser from these barsCharting by TradingView Lightweight Charts™
XBRL company facts, SEC EDGAR. TTM = last four reported quarters. Valuation ratios arrive with a price source — we don't fake quotes.
Has ODTX been issuing shares? Offering history →
↓ Download the fiscal-year statement table: XLSX · CSV · revenue, income, EPS, cash flow, balance sheet · from SEC XBRL, dated
As filed. We do not recategorize line items. Each chart plots one XBRL concept exactly as ODTX tagged it: revenue us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, net income us-gaap:NetIncomeLoss, EPS us-gaap:EarningsPerShareDiluted, period by period; a period the company did not tag on its own is left out, not estimated. A figure that disagrees with the filing is a bug in our extraction, not a policy, and we fix it: report a mismatch.
A plain-English read on ODTX plus an auto-SWOT, built from ODTX's SEC filings and market data, every point cited, nothing invented. Educational, not investment advice.
Four AI analysts, a bull, a bear, a risk manager, and a PM, debate ODTX using only the SEC-filing and market facts below. Every point cites its evidence; nothing is invented. This is educational research, not investment advice.
Ask about ODTX’s revenue, earnings, valuation, filings, insiders or Congress trades. Answers come only from the numbered evidence the research brief uses, each citing the items it rests on. A question about one figure is answered by code, free. One that puts figures together is 1 generation (Pro). A question about whether to buy, sell or hold, how much, or where the price goes gets a refusal.
Educational only — not financial advice. Data from SEC EDGAR public filings; no live market data is shown. Figures reflect the company's own reported XBRL facts and may lag.
On file for ODTX from Nov 3, 2026 to Nov 16, 2026: filing deadline (below).
| Event | Result |
|---|---|
| Earnings date | nothing in the window. No date in the window: no regular report cadence in the filings. |
| Filing deadline | on file. In the window: the 10-Q for the quarter ending Sep 30, 2026, due 40 to 45 days after it as SEC states no filer status for it, the span covers every status, falls due between Nov 9, 2026 and Nov 16, 2026. Newest periodic report on file: the 10-Q for the period ending Jun 30, 2026, filed Aug 6, 2026. filing list on EDGAR |
| Ex-dividend date | not covered. Not checked. This attestation does not cover ex-dividend dates. |
This records what these sources returned when they were read. It is not a forecast: a company can announce an event at any time, and ex-dividend dates are not covered. Window 2026-11-03 to 2026-11-16, Eastern dates. Deadlines follow SEC Rules 13a-1 and 13a-13 and Form 20-F, moved past weekends and federal holidays by Rule 0-3.
Group: Biological Products, (No Diagnostic Substances), the SEC industry code ODTX files under. 4 companies in our stored table file under it.
| Metric | ODTX | Group median | 25th to 75th percentile | Where ODTX sits |
|---|---|---|---|---|
| Net marginnet income divided by revenue, same fiscal year | Withheld: 4 companies in this SIC group have the figure on file, and a group prints from 6. | |||
| Free cash flow marginoperating cash flow less capital expenditure, divided by revenue, same fiscal year | Withheld: 4 companies in this SIC group have the figure on file, and a group prints from 6. | |||
| Return on equitynet income divided by stockholders’ equity at the fiscal year end | Withheld: 4 companies in this SIC group have the figure on file, and a group prints from 6. | |||
One filed metric per row, each a ratio of two figures from the same annual report; no composite and no grade. Percentile is the share of the group’s other companies with a lower figure. A group prints from 6 companies with the figure. The group is drawn from our stored table (the S&P 500 issuers and the companies we cover, each with its newest annual report read), not from every filer in the class. Industry pages show the same medians by group.
Projected from ODTX's own SEC 8-K filing history — the year-over-year reporting pattern (about 47% land the exact day, about 91% within a week, measured across 4,713 past reports). No analyst estimates and nothing invented, and every confirmed date links to the source it came from, so you can check it yourself. It upgrades the momentODTX files or announces.
| Reported | Close-to-close |
|---|---|
| 2026-08-04 | +15.2% |
| 2026-06-17 | +6.7% |
Earnings dates are the company's 8-K Item 2.02 filings (SEC). Reactions from Databento EOD.
Volume against its own history: 61% of its last 122 sessions were lighter than the last one, the 2026-11-02 session. End-of-day bars (Databento). Volume detail
Closes only, split-adjusted. Range of the 123 sessions on file, under a full year. An average needs that many sessions on file to print. These are measurements, not support, resistance or targets. Chart with studies
No lawmaker has disclosed a trade in ODTX under the STOCK Act.
Withheld: 200-session average (needs 200 sessions; 123 are on file).
Daily closes from 2026-05-08 through 2026-11-02, 123 sessions, split-adjusted, history before 2026-05-08 left out at a corporate action. No direction, pattern, entry, target or overbought label: these are measurements. Filings dated on the move days are in ODTX’s filings; the chart with studies draws every figure.
Written by code from 123 end-of-day bars through 2026-11-02. Written by code from the data on file, not by a model. Information, not investment advice: it describes the security and recommends nothing to anyone.
Total return including reinvested dividends, from ODTX’s adjusted closing prices. Past return is not a forecast and not investment advice.
No fair value band on this page build. No annual filing figures reached the estimators, either because the SEC read did not finish or because ODTX has not filed annual figures yet. That is a statement about the read, not about ODTX’s value. The page rebuilds daily.
Every refusal recorded for ODTX → · How often we decline, and why →
No tracked institution reported a position in ODTX in the latest 13F round.
Every registered fund files its complete portfolio with the SEC. These weights come from those filings, so each one carries the period it describes. Holdings are quarterly and filed in arrears — the figures below are as of 2026-06-30, not today.
| Fund | Weight | As of |
|---|---|---|
| VTI Vanguard Total Stock Market ETF | <0.01% | 2026-06-30 |
Drawn from 38 large US equity funds we scan, not every fund in existence, so a missing fund means we do not scan it rather than that it holds none. Holdings are joined to tickers by issuer name, which does not resolve every position; what that misses is published.
Head office: Boston, Massachusetts, United States · the company’s charter and its head office are in different states.
Source: the cover page of Odyssey Therapeutics, Inc.’s 10-Q filed 2026-08-06, on EDGAR. Filings checked 2026-11-03. Incorporation is where the company’s charter was filed. It is not where the business operates or earns, which no filing cover states. How this works
Of 1 sale in the last ~6 months, 0 were filed with the Rule 10b5-1 box checked, set up in advance under a written trading plan; 1 was filed without it.
| TPG GP A, LLCInsider | BUY | $25.0M | view → |
| Dimension Capital II, L.P.Director | BUY | $20.0M | view → |
| SR ONE CAPITAL MANAGEMENT, LLC10% owner | SELL | $32K | view → |
| SR ONE CAPITAL MANAGEMENT, LLC10% owner | BUY | $10.0M | view → |
| LEIDEN JEFFREY MDirector | BUY | $100K | view → |
| Haas JasonChief Financial Officer | BUY | $20K | view → |
| Li Nan (LN)Director | BUY | $20.0M | view → |
| Chu ShelleyDirector | BUY | $200K | view → |
1 of the 1 checks that ran found nothing new for ODTX. 3 could not run.
Each event check looks back 30 days from the date its own source was stored, read or generated, never from the date this page was built. A check that finds nothing is a measurement of that window, not a forecast, and a check that cannot be dated does not make the claim at all.
From SEC Form 4 and 13F filings. Both are backward-looking disclosures on different reporting clocks, and neither predicts price. Educational information only — not investment advice.